CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

CAT

857.12

-6.25%↓

GE

319.5

-3.32%↓

GEV.US

866.14

-5.57%↓

RTX

177.9

-1.87%↓

BA

209.07

-2.53%↓

Inicio・Lista de Acciones・Ocugen Inc

Search

Ocugen Inc

Cerrado

1.18 -4.07

Resumen

Variación precio

24h

Actual

Mínimo

1.18

Máximo

1.24

Métricas clave
By Trading Economics
Ingresos	-1.5M -19M
Ventas	1.7M 1.5M
BPA	-0.06
Margen de beneficios	-1,250.946
Empleados	116
EBITDA	-987K -17M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+821.77% upside

Dividendos
By Dow Jones
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-193M 433M
Apertura anterior	5.25
Cierre anterior	1.18

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 jun 2026, 23:36 UTC

Ganancias

Correction to Oracle Reports Higher 4Q Profit Article

10 jun 2026, 23:19 UTC

Acciones populares

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 jun 2026, 23:09 UTC

Principales Movimientos del Mercado

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 jun 2026, 23:04 UTC

Ganancias

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 jun 2026, 20:44 UTC

Principales Movimientos del Mercado

Caterpillar Raises Quarterly Dividend 8%

10 jun 2026, 23:49 UTC

Adquisiciones, fusiones, absorciones

Elliott: Northern Star Should Take No Options Off The Table

10 jun 2026, 23:48 UTC

Adquisiciones, fusiones, absorciones

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 jun 2026, 23:48 UTC

Adquisiciones, fusiones, absorciones

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 jun 2026, 23:47 UTC

Charlas de Mercado

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 jun 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 jun 2026, 23:46 UTC

Adquisiciones, fusiones, absorciones

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 jun 2026, 23:38 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

10 jun 2026, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

10 jun 2026, 23:38 UTC

Charlas de Mercado

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 jun 2026, 23:32 UTC

Charlas de Mercado

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 jun 2026, 23:20 UTC

Charlas de Mercado

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 jun 2026, 22:05 UTC

Charlas de Mercado

Correction to Bank of Canada Stays on Hold Market Talk

10 jun 2026, 21:57 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:52 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:35 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 21:22 UTC

Ganancias

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 jun 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

10 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

10 jun 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

10 jun 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

10 jun 2026, 20:39 UTC

Charlas de Mercado

Ganancias

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 jun 2026, 20:34 UTC

Ganancias

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 jun 2026, 20:33 UTC

Ganancias

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 jun 2026, 20:33 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

10 jun 2026, 20:33 UTC

Charlas de Mercado

Ganancias

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

821.77% repunte

Estimación a 12 Meses

Media 11.43 USD 821.77%

Máximo 22 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Otras acciones del sector

CAT

Caterpillar Inc.

857.12

GE

General Electric Co.

319.5

GEV.US

GE Vernova LLC

866.14

RTX

Raytheon Technologies Corp.

177.9

BA

Boeing Co.

209.07

Live chat